AVN Insider Trading Activity and SEC Form 4 Filings
AVN insider trading summary
No open-market insider purchases or sales of Avanir Pharmaceuticals (AVN) have been reported on SEC Form 4 in the past 12 months.
Latest AVN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 31, 2006 | Orbimed Advisors LLC | Director | Sell | $6.2M (629,121 @ $9.79) |
| May 31, 2006 | Samuel D Isaly | Director | Sell | $6.2M (629,121 @ $9.79) |
| May 31, 2006 | Orbimed Capital II LLC | Director | Sell | $6.2M (629,121 @ $9.79) |
| Feb 17, 2006 | Jagadish C Sircar | VP of Drug Discovery | Sell | $61K (3,600 @ $16.82) |
| Feb 14, 2006 | David J Mazzo | Director | Buy | $16K (1,000 @ $15.59) |
| Oct 20, 2005 | Jonathan Silverstein | Director | Buy | $1.5M (566,038 @ $2.65) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.